THE MECHANISMS OF THE RESISTANCE TO ANDROGEN ABLATION TREATMENT IN PROSTATE CANCER CELLS

被引:0
|
作者
Cal, Cag [1 ]
Simsir, Adnan [1 ]
机构
[1] Ege Univ, Tip Fak, Urol Anabilim Dali, Izmir, Turkey
来源
TURKISH JOURNAL OF UROLOGY | 2005年 / 31卷 / 01期
关键词
Prostate neoplasm; androgen ablation; resistance; mechanism;
D O I
暂无
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Introduction: Prostate neoplasm is an important health problem, which is especially common in older age men. Although the standard treatment of metastatic prostate neoplasm is androgen ablation, the resistance to the treatment will develop in most of the patients, in time. There is no efficient treatment modality for these patients. It is required to determine the changes in prostate cancer cells to prevent the development of treatment resistance. Androgens are important in prostate development, and the androgen ablation and receptor blockade are effective treatment modalities in prostate cancer. For these reasons, it is inevitable for androgen receptors to play a role in the development of resistance to hormonal treatment. Since prostate cancer is a heterogeneous disease, it is necessary to investigate the different mechanisms which may have a role in e disease progression.
引用
收藏
页码:21 / 30
页数:10
相关论文
共 50 条
  • [41] Diversity of Resistance Mechanisms in Prostate Cancer after Neoadjuvant Intense Androgen Deprivation Therapy
    Ye, Huihui
    Sowalsky, Adam G.
    Schaefer, Rachel
    Yuan, Xin
    Chen, Shao-yong
    Gerrin, Sean J.
    Montaser, Laleh
    Ma, Fen
    Voznesensky, Olga
    Cai, Changmeng
    Lis, Rosina
    Zhang, Zhenwei
    Loda, Massimo
    Taplin, Maly-Ellen
    Balk, Steven
    MODERN PATHOLOGY, 2016, 29 : 271A - 271A
  • [42] Androgen Receptor Targeting Drugs in Castration-Resistant Prostate Cancer and Mechanisms of Resistance
    Crona, D. J.
    Milowsky, M. I.
    Whang, Y. E.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2015, 98 (06) : 582 - 589
  • [43] Mechanisms of drug resistance that target the androgen axis in castration resistant prostate cancer (CRPC)
    Penning, Trevor M.
    JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 2015, 153 : 105 - 113
  • [44] Diversity of Resistance Mechanisms in Prostate Cancer after Neoadjuvant Intense Androgen Deprivation Therapy
    Ye, Huihui
    Sowalsky, Adam G.
    Schaefer, Rachel
    Yuan, Xin
    Chen, Shao-Yong
    Gerrin, Sean J.
    Montaser, Laleh
    Ma, Fen
    Voznesensky, Olga
    Cai, Changmeng
    Lis, Rosina
    Zhang, Zhenwei
    Loda, Massimo
    Taplin, Mary-Ellen
    Balk, Steven
    LABORATORY INVESTIGATION, 2016, 96 : 271A - 271A
  • [45] Intracrine androgen metabolism in prostate cancer progression: mechanisms of castration resistance and therapeutic implications
    Mostaghel, Elahe A.
    Nelson, Peter S.
    BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM, 2008, 22 (02) : 243 - 258
  • [46] Androgen Receptor-Dependent and -Independent Mechanisms Involved in Prostate Cancer Therapy Resistance
    Crona, Daniel J.
    Whang, Young E.
    CANCERS, 2017, 9 (06)
  • [47] Mechanisms of resistance to treatment in metastatic castration resistant prostate cancer
    Araujo, Antonio
    MEDICINE, 2016, 95 (10)
  • [48] Current uses and resistance mechanisms of enzalutamide in prostate cancer treatment
    Miller, Carly D.
    Likasitwatanakul, Pornlada
    Toye, Eamon
    Hwang, Justin H.
    Antonarakis, Emmanuel S.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2024, 24 (11) : 1085 - 1100
  • [49] Androgen deprivation treatment in prostate cancer
    Thomas, Benjamin C.
    Neal, David E.
    BMJ-BRITISH MEDICAL JOURNAL, 2013, 346
  • [50] Androgen resistance in prostate cancer is associated with an enrichment of stem-like cells
    Wu, Lisa Y.
    Bansal, Nitu
    Liu, Tiancheng
    Berkman, Clifford E.
    Bertino, Joseph R.
    CANCER RESEARCH, 2014, 74 (19)